IRD Stock Catalyst: Opus Genetics Announces Positive Results from LYNX-2 Phase 3 Trial

Opus Genetics, Inc. (Nasdaq: IRD) announced on June 2, 2025, that its LYNX-2 Phase 3 trial met its primary endpoint. The trial evaluated Phentolamine Ophthalmic Solution 0.75% in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions.

The trial demonstrated a ≥15-letter (≥3-line) gain in 17.3% of patients treated with Phentolamine Ophthalmic Solution 0.75%, compared to 9.2% in the placebo group. A total of 199 patients participated in the study.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.